Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Non T-cell depleted haploidentical vs. matched sibling donor HSCT in adult ALL in remission

Arnon Nagler • 1 Feb 2021
TCT 2021
Acute Lymphoblastic Leukemia Leukemia

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the results of a study evaluating non-T-cell depleted haploidentical vs. matched sibling donor hematopoietic stem cell transplantation (HSCT) in adult patients with acute lymphoblastic leukemia (ALL). The results of this retrospective analysis demonstrate no difference in overall survival between the outcomes of adult patients with ALL receiving an allogeneic stem cell transplant from haploidentical donors or haplo and sibling donors. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals